4th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 24 - April 22, 2023 - Virtual Platform will remain open through April 22

Virtual Access to the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop will be available through April 22.

If you were unable to attend this meeting, there is still time to register and watch the video content.

Building upon the success of prior workshops, the International Myeloma Society is happy to host the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop to discuss immune-based therapies in myeloma including the latest CAR T cell and bispecific T cell-engager clinical data, promising preclinical leads, updated correlative analyses exploring predictors of response and resistance mechanisms, and next-generation manufacturing and CAR construct approaches, including “off-the-shelf” allogeneic and NK-cell based strategies.  This year we are also including a session on real-world considerations, including how to potentially sequence immune-based therapies for myeloma, as well as best practices for infection prevention following T cell-directed therapies.


Our sponsors:

Registration Rates

Registration Category Virtual Rate
Member $0.00
Non-Member $100.00
Non-Members in Training $50.00
Pharma Industry $150.00


Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events